Developer docs
API playgroundTry for free, no card

Search company profiles

Neurosoft Bioelectronics

Full company profile

uuid0000v1z

Namestring
Neurosoft Bioelectronics
Legal namestring
Neurosoft Bioelectronics SA
Company typeenum
Private
Founded yearint
2015
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGeneva, Switzerland
HQ citystring
Geneva
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
brain-computer interfaces, neurotechnology medical devices, soft electrode implants, tinnitus treatment devices, minimally invasive neurodevices
Industry3 codes
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLAHAEAD
Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Neurotechnology / Brain-Computer Interface Medical Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Brain-Computer Interface Medical Devices
TypeHardware Sales
Description

Pre-commercial stage. The company is developing implantable BCI systems for treating neurological conditions including epilepsy, tinnitus, and motor disorders. Revenue expected from device sales and related medical services upon regulatory approval.

pulse2.com
2Clinical Trial Services
TypeProfessional Services
Description

Providing BCI technology for clinical research conducted at partner institutions including UTHealth Houston and UMC Utrecht.

pulse2.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Personnel, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1SOFT ECoG™
Description

A family of subdural electrodes for brain signal recording or stimulation intra-operatively or for up to 30 days, built on the soft brain interface technology platform.

neurosoft-bio.com
+3 more records
Core offering1 text field

Neurosoft Bioelectronics develops and manufactures soft, minimally invasive brain-computer interface (BCI) medical devices for monitoring and treating neurological disorders including epilepsy, severe tinnitus, and motor disabilities. The company's proprietary technology platform produces soft electrodes that are 1,000 to 100,000 times softer than alternatives, enabling minimally invasive implantation through burr holes and integration with AI for biomarker detection and neural decoding.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 130% better outcome compared to CBT for tinnitus treatment in clinical study
+2 more records
Product overview1 text field

Neurosoft Bioelectronics develops a portfolio of soft, stretchable brain-computer interface products built on its proprietary technology platform. The core platform provides soft electrodes that are 1,000 to 100,000 times softer than alternatives. Key products include SOFT ECoG™ (subdural electrode arrays for sub-chronic brain recording/stimulation up to 30 days), MINDZ™ (minimally invasive implantable brain interface deployed via burr hole), SOFT TINNIT™ (fully implantable closed-loop system for severe tinnitus treatment), and Synapsuit (BCI-controlled soft wearable exosuit for upper-limb motor disabilities). The company integrates AI throughout its platform for biomarker detection, neuromodulation optimization, and motor/speech decoding.

Product and service5 records
1Soft Brain Interface Technology Platform
CategoryCore Technology Platform
Description

Proprietary soft, elastic brain interface technology platform with electrodes that are 1,000 to 100,000 times softer and 3-5 times thinner than alternative solutions, providing enhanced bio-integration and minimized mechanical mismatch with neural tissues. The platform reduces scar tissue formation, subdural hematomas, and brain compression risks while enabling minimally invasive implantation through burr holes.

2SOFT ECoG™
CategoryNeurotechnology Medical Device
Description

Subdural electrode arrays for brain signal recording or stimulation intended for intra-operative use or up to 30 days of sub-chronic use. Used for identifying epileptogenic brain tissue in drug-resistant epilepsy patients and for brain mapping/monitoring during resection surgeries.

3MINDZ™
CategoryNeurotechnology Medical Device
Description

Minimally invasive brain interface implantable on the brain surface using a deployment system that leverages soft mechanical properties allowing folding/unfolding without damage. First application supports localization of epileptic foci for drug-resistant epilepsy patients through burr hole insertion.

4SOFT TINNIT™
CategoryNeurotechnology Medical Device
Description

Fully implantable closed-loop brain-computer interface system specifically designed to treat severe tinnitus by uniquely targeting and neuromodulating specific areas of the brain to suppress or significantly reduce perceived ringing. Based on neurofeedback approach that achieved 130% better outcomes compared to CBT in clinical studies.

5Synapsuit
CategoryNeurotechnology Medical Device
Description

Brain-computer interface system with AI algorithm to decode brain signals and control a lightweight soft wearable exosuit for supporting arm and hand movements in real time for patients with severe upper-limb motor disabilities. Developed in collaboration with Wyss Center, Korea Electronics Technology Institute, and Jang EUN FnC.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierInfrastructureTypeTechnology or IntegrationAnnounced on2026-05-18
Description

Awarded computational access to Alps supercomputer (ranked 8th globally) to train neural decoding models using proprietary soft electrode technology.

2Science Corporation
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-20
Description

Multiyear, multimillion-dollar partnership granting Neurosoft access to Science's full stack of clinical-grade neural recording tools within the Science BCI Ecosystem. This collaboration reduces BCI development costs from $75-100 million to under $5 million for first-in-human trials. Neurosoft develops implantable BCI systems for treating tinnitus, epilepsy, and other neurological disorders. Neurosoft is the inaugural inductee into Science Corp's academic access program.

biospace.com
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Collaboration on Synapsuit project for BCI-controlled exosuit technology for upper limb motor disabilities.

Strategic tierProjectTypeStrategic or Co-development Partner
Description

Collaboration on Synapsuit project for soft wearable exosuit technology.

Strategic tierProjectTypeStrategic or Co-development Partner
Description

Collaboration on Synapsuit project for BCI-controlled exosuit technology.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers9 records
TypeDirect peer
Description

Synchron is a direct competitor developing implantable brain-computer interfaces (Stentrode) targeting motor restoration in paralysis. Both are clinical-stage BCI companies pursuing implantable neural interfaces, with Synchron further along in human trials.

TypeDirect peer
Description

Blackrock Neurotech is a direct peer in implantable BCIs using Utah Array-style electrode systems for motor and speech restoration. They have the largest implanted BCI patient base, providing the most direct comparable for Neurosoft's clinical and regulatory path.

TypeBroad incumbent
Description

Neuralink is the highest-profile implantable BCI company developing high-bandwidth neural interfaces. As a much larger, well-capitalized player with its own FDA-approved human trial, it defines the competitive backdrop for Neurosoft's clinical and commercial strategy.

TypeDirect peer
Description

Paradromics is a direct BCI peer building high-data-rate implantable neural interfaces for speech and motor restoration. Both companies are clinical-stage with comparable funding scale and a focus on minimally invasive neural recording.

TypeDirect peer
Description

Precision Neuroscience is a direct peer developing a high-electrode-count cortical interface (Layer 7) for clinical and BCI applications. Both companies compete for FDA pathways in implantable cortical recording and share the neuromodulation/neuro-monitoring overlap with Neurosoft's SOFT ECoG.

TypeEmerging player
Description

Inbrain Neuroelectronics is an emerging BCI peer developing graphene-based neural interfaces for neuromodulation in Parkinson's and epilepsy. It overlaps with Neurosoft's MINDZ/SOFT ECoG epilepsy applications and shares a similar European clinical-stage profile.

TypeDirect peer
Description

CorTec is a German company developing implantable brain-computer interfaces and electrode technology for research and clinical applications. Both companies serve the implantable neuro-interface market with a focus on long-term, biocompatible neural recording and stimulation.

TypeDirect peer
Description

MicroProbes manufactures microelectrodes and neural recording/stimulation arrays used in preclinical neuroscience and BCI research. Both companies supply electrode-based neural interface technology for clinical and research applications, with overlapping customer profiles in academic medical centers.

TypeBroad incumbent
Description

Neuronetics is a publicly listed neuromodulation company commercializing transcranial magnetic stimulation (NeuroStar) for depression. While non-invasive, it is a relevant comparable for the clinical/commercial pathway Neurosoft will face with SOFT TINNIT in neurology indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks2 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Neurosoft Bioelectronics

Neurotechnology / Brain-Computer Interface Medical Devicesneurosoft-bio.com

Neurosoft Bioelectronics firmographics

Firmographics
Name
Neurosoft Bioelectronics
Legal name
Neurosoft Bioelectronics SA
Website
https://neurosoft-bio.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Neurosoft Bioelectronics industry classification

Industry
Product category
Neurotechnology / Brain-Computer Interface Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLAHAEAD
Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)

Keywords

  • Brain-computer interfaces
  • Neurotechnology medical devices
  • Soft electrode implants
  • Tinnitus treatment devices
  • Minimally invasive neurodevices

Where Neurosoft Bioelectronics is headquartered

Location

Headquarters

HQ city
Geneva
HQ country
Switzerland
HQ region
Europe

Offices3 records

Markets served

Neurosoft Bioelectronics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Infrastructure, Marketing or Sales

Revenue model

  1. Brain-Computer Interface Medical Devices: Pre-commercial stage. The company is developing implantable BCI systems for treating neurological conditions including epilepsy, tinnitus, and motor disorders. Revenue expected from device sales and related medical services upon regulatory approval.
  2. Clinical Trial Services: Providing BCI technology for clinical research conducted at partner institutions including UTHealth Houston and UMC Utrecht.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Neurosoft Bioelectronics product offering

Product offering

Core offering

Neurosoft Bioelectronics develops and manufactures soft, minimally invasive brain-computer interface (BCI) medical devices for monitoring and treating neurological disorders including epilepsy, severe tinnitus, and motor disabilities. The company's proprietary technology platform produces soft electrodes that are 1,000 to 100,000 times softer than alternatives, enabling minimally invasive implantation through burr holes and integration with AI for biomarker detection and neural decoding.

Product overview

Neurosoft Bioelectronics develops a portfolio of soft, stretchable brain-computer interface products built on its proprietary technology platform. The core platform provides soft electrodes that are 1,000 to 100,000 times softer than alternatives. Key products include SOFT ECoG™ (subdural electrode arrays for sub-chronic brain recording/stimulation up to 30 days), MINDZ™ (minimally invasive implantable brain interface deployed via burr hole), SOFT TINNIT™ (fully implantable closed-loop system for severe tinnitus treatment), and Synapsuit (BCI-controlled soft wearable exosuit for upper-limb motor disabilities). The company integrates AI throughout its platform for biomarker detection, neuromodulation optimization, and motor/speech decoding.

Differentiator

Problem solved

Functional benefit

Brands

  • SOFT ECoG™: A family of subdural electrodes for brain signal recording or stimulation intra-operatively or for up to 30 days, built on the soft brain interface technology platform.
  • MINDZ™
  • SOFT TINNIT™
  • Synapsuit

Products and services

  • Soft Brain Interface Technology Platform Proprietary soft, elastic brain interface technology platform with electrodes that are 1,000 to 100,000 times softer and 3-5 times thinner than alternative solutions, providing enhanced bio-integration and minimized mechanical mismatch with neural tissues. The platform reduces scar tissue formation, subdural hematomas, and brain compression risks while enabling minimally invasive implantation through burr holes.
  • SOFT ECoG™ Subdural electrode arrays for brain signal recording or stimulation intended for intra-operative use or up to 30 days of sub-chronic use. Used for identifying epileptogenic brain tissue in drug-resistant epilepsy patients and for brain mapping/monitoring during resection surgeries.
  • MINDZ™ Minimally invasive brain interface implantable on the brain surface using a deployment system that leverages soft mechanical properties allowing folding/unfolding without damage. First application supports localization of epileptic foci for drug-resistant epilepsy patients through burr hole insertion.
  • SOFT TINNIT™ Fully implantable closed-loop brain-computer interface system specifically designed to treat severe tinnitus by uniquely targeting and neuromodulating specific areas of the brain to suppress or significantly reduce perceived ringing. Based on neurofeedback approach that achieved 130% better outcomes compared to CBT in clinical studies.
  • Synapsuit Brain-computer interface system with AI algorithm to decode brain signals and control a lightweight soft wearable exosuit for supporting arm and hand movements in real time for patients with severe upper-limb motor disabilities. Developed in collaboration with Wyss Center, Korea Electronics Technology Institute, and Jang EUN FnC.

Quantifiable outcome

  • 130% better outcome compared to CBT for tinnitus treatment in clinical study
  • +2 more outcomes

Companies that use Neurosoft Bioelectronics

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Neurosoft Bioelectronics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature7 records

Neurosoft Bioelectronics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered infrastructure, core, major and project.

  • CSCS (Swiss National Supercomputing Centre)infrastructureTechnology or Integration · 18 May 2026Awarded computational access to Alps supercomputer (ranked 8th globally) to train neural decoding models using proprietary soft electrode technology.
  • Science CorporationcoreStrategic or Co-development Partner · 20 February 2026Multiyear, multimillion-dollar partnership granting Neurosoft access to Science's full stack of clinical-grade neural recording tools within the Science BCI Ecosystem. This collaboration reduces BCI development costs from $75-100 million to under $5 million for first-in-human trials. Neurosoft develops implantable BCI systems for treating tinnitus, epilepsy, and other neurological disorders. Neurosoft is the inaugural inductee into Science Corp's academic access program.
  • Wyss CentermajorStrategic or Co-development PartnerCollaboration on Synapsuit project for BCI-controlled exosuit technology for upper limb motor disabilities.
  • Korea Electronics Technology InstituteprojectStrategic or Co-development PartnerCollaboration on Synapsuit project for soft wearable exosuit technology.
  • Jang EUN FnCprojectStrategic or Co-development PartnerCollaboration on Synapsuit project for BCI-controlled exosuit technology.

Scale indicators6 records

Recent moves6 records

Expansion highlights7 records

Neurosoft Bioelectronics competitors and assessment

Company assessment

Direct peers

  • Synchron: Synchron is a direct competitor developing implantable brain-computer interfaces (Stentrode) targeting motor restoration in paralysis. Both are clinical-stage BCI companies pursuing implantable neural interfaces, with Synchron further along in human trials.
  • Blackrock Neurotech: Blackrock Neurotech is a direct peer in implantable BCIs using Utah Array-style electrode systems for motor and speech restoration. They have the largest implanted BCI patient base, providing the most direct comparable for Neurosoft's clinical and regulatory path.
  • Paradromics: Paradromics is a direct BCI peer building high-data-rate implantable neural interfaces for speech and motor restoration. Both companies are clinical-stage with comparable funding scale and a focus on minimally invasive neural recording.
  • Precision Neuroscience: Precision Neuroscience is a direct peer developing a high-electrode-count cortical interface (Layer 7) for clinical and BCI applications. Both companies compete for FDA pathways in implantable cortical recording and share the neuromodulation/neuro-monitoring overlap with Neurosoft's SOFT ECoG.
  • CorTec: CorTec is a German company developing implantable brain-computer interfaces and electrode technology for research and clinical applications. Both companies serve the implantable neuro-interface market with a focus on long-term, biocompatible neural recording and stimulation.
  • MicroProbes for Life Science & Research: MicroProbes manufactures microelectrodes and neural recording/stimulation arrays used in preclinical neuroscience and BCI research. Both companies supply electrode-based neural interface technology for clinical and research applications, with overlapping customer profiles in academic medical centers.

Broad incumbents

  • Neuralink: Neuralink is the highest-profile implantable BCI company developing high-bandwidth neural interfaces. As a much larger, well-capitalized player with its own FDA-approved human trial, it defines the competitive backdrop for Neurosoft's clinical and commercial strategy.
  • Neuronetics: Neuronetics is a publicly listed neuromodulation company commercializing transcranial magnetic stimulation (NeuroStar) for depression. While non-invasive, it is a relevant comparable for the clinical/commercial pathway Neurosoft will face with SOFT TINNIT in neurology indications.

Emerging players

  • Inbrain Neuroelectronics: Inbrain Neuroelectronics is an emerging BCI peer developing graphene-based neural interfaces for neuromodulation in Parkinson's and epilepsy. It overlaps with Neurosoft's MINDZ/SOFT ECoG epilepsy applications and shares a similar European clinical-stage profile.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks2 records

Key highlights7 records

Customer concentration

Neurosoft Bioelectronics social profiles

Digital presence

Neurosoft Bioelectronics compliance and trust

Trust signal

Compliance1 record

Neurosoft Bioelectronics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Neurosoft Bioelectronics leadership team

Management profile

Number of profiles

Profiles17 records

Neurosoft Bioelectronics funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Neurosoft Bioelectronics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neurosoft Bioelectronics

What does Neurosoft Bioelectronics do?

Neurosoft Bioelectronics develops and manufactures soft, minimally invasive brain-computer interface (BCI) medical devices for monitoring and treating neurological disorders including epilepsy, severe tinnitus, and motor disabilities. The company's proprietary technology platform produces soft electrodes that are 1,000 to 100,000 times softer than alternatives, enabling minimally invasive implantation through burr holes and integration with AI for biomarker detection and neural decoding.

Is Neurosoft Bioelectronics a public or private company?

Neurosoft Bioelectronics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Neurosoft Bioelectronics founded?

Neurosoft Bioelectronics was founded in 2015. It employs 11 to 50 people.

Where is Neurosoft Bioelectronics based?

Neurosoft Bioelectronics is headquartered in Geneva, Switzerland, in the Europe region.

How does Neurosoft Bioelectronics make money?

Two revenue lines are on record. Brain-Computer Interface Medical Devices are the primary driver. The others are clinical Trial Services.

Who are Neurosoft Bioelectronics's main competitors?

Direct peers on record are Synchron, Blackrock Neurotech, Paradromics, Precision Neuroscience, CorTec and MicroProbes for Life Science & Research. Broad incumbents are Neuralink and Neuronetics. Inbrain Neuroelectronics is listed as an emerging player.

Does Neurosoft Bioelectronics have an API?

No public API is recorded for Neurosoft Bioelectronics.

What industry is Neurosoft Bioelectronics in?

Neurosoft Bioelectronics's product category is Neurotechnology / Brain-Computer Interface Medical Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS), with a secondary code of HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
startupticker.chAwards for Western Switzerland StartupsWestern Switzerland startups won awards in chip-to-chip connectivity, brain-computer interfaces, and building energy optimization. Kandou AI received the 2026 EU Demo of the Year award and closed $225mm in funding; Neurosoft Bioelectronics won a gold medal in China's biotech competition; YORD's heating system saved 4.19 GWh and 1,046 metric tons of CO2.BioAlpsNeurosoft Bioelectronics, Givaudan and Bracco Honoured at Geneva’s Grands Prix de l’économieOn 17 September, Neurosoft Bioelectronics, Givaudan, and Bracco received prizes at Geneva's Grands Prix de l'économie ceremony. Neurosoft won the Innovation Prize for its soft brain-computer interfaces, Givaudan the International Influence Prize, and Bracco the Industry Prize. Lombard Odier and the Fondation pour Genève also received awards.VestbeeTop European funding rounds closed in May 2026European startups closed funding rounds in May 2026, including Cytospire Therapeutics' £61M Series A and eleQtron's €57M Series A. The rounds span immuno-oncology, quantum computing, AI, and biotech, with capital used for clinical trials, scaling, and expansion.Pulse 2.0Neurosoft Bioelectronics: $7.5 Million Seed Round Closed To Advance Stretchable Brain-Computer InterfacesNeurosoft Bioelectronics closed a $7.5 million oversubscribed seed financing round led by Skybound Venture Capital, with participation from PL Capital, IAG Capital Partners, and Connecticut Innovations, bringing total funding raised to over $20 million. The funding will support development of the company's stretchable brain-computer interface platform, which has been tested in 10 patients across two ongoing clinical trials at UTHealth Houston and UMC Utrecht. The company has established GMP manufacturing in Switzerland, obtained ISO 13485 certification, and engaged with the FDA through multiple pre-submission meetings to support regulatory pathway for its first commercial product in the United States.startupticker.chMarket leaders in the makingSwiss deeptech start-ups are reaching initial market milestones quickly, with DePoly securing CHF 50 million in contracts for its demonstration plant and Voltiris opening a one-hectare facility in the Netherlands. Neurosoft Bioelectronics raised USD 7.5 million in a seed round, and the article notes the ecosystem still has room for improvement.Medical Device NetworkNeurosoft Bioelectronics raises $7.5m to progress BCI developmentNeurosoft Bioelectronics raised $7.5M in a seed round led by Skybound Venture Capital to advance its brain-computer interface. The funds will support clinical trials and US commercialization, with the company having evaluated its BCI in 10 patients. It also plans to build a neural data platform for a cortical foundation model.BioSpaceNeurosoft Bioelectronics Closes $7.5M Oversubscribed Seed Round to Build Stretchable and Scalable Brain-Computer InterfacesNeurosoft Bioelectronics, a neurotechnology company headquartered in Switzerland with a US presence in New York, announced the closing of a $7.5 million oversubscribed seed financing round led by Skybound Venture Capital, with participation from PL Capital, IAG Capital Partners, and Connecticut Innovations. The funding brings the company's total raised to date to over $20 million and will support clinical trials in the US and Europe, where the company has already tested its brain-computer interface in 10 patients across two ongoing studies. The company is also developing a cortical foundation model trained on high-quality neural recordings from its implantable devices, with an earlier partnership announced with Science Corp to accelerate its BCI platform development.citybizNeurosoft Bioelectronics Raises $7.5M to Scale Brain-Computer Interface PlatformNeurosoft Bioelectronics has raised a $7.5 million oversubscribed seed round to scale its soft, stretchable brain-computer interface platform, with financing bringing its total funding to more than $20 million. The company plans to use the funding to demonstrate minimally invasive deployment in human patients and pursue commercialization of its first brain interface product in the United States, while building what it calls a "foundation model" of the human cortex using large-scale neural recordings. The funding reflects broader investor interest in neurotechnology as advances in AI and computational neuroscience push the sector beyond academic research toward commercially viable healthcare applications, with the company having already tested its technology in 10 patients through clinical studies at UTHealth Houston and UMC Utrecht.MassDeviceNeurosoft Bioelectronics closes $7.5M seed funding round to support BCINeurosoft Bioelectronics closed a $7.5 million seed round led by Skybound Venture Capital, bringing total funding to over $20 million. The company is developing minimally invasive BCI systems for tinnitus and epilepsy, with 10 human implants across two trials. It plans to advance clinical trials and achieve U.S. commercialization.